NOVO.B.DK

304

-1.31%↓

GMAB.DK

2,011

-0.49%↓

HLUNB.DK

42.86

+0.05%↑

ZEAL.DK

465.2

+1.48%↑

NOVO.B.DK

304

-1.31%↓

GMAB.DK

2,011

-0.49%↓

HLUNB.DK

42.86

+0.05%↑

ZEAL.DK

465.2

+1.48%↑

NOVO.B.DK

304

-1.31%↓

GMAB.DK

2,011

-0.49%↓

HLUNB.DK

42.86

+0.05%↑

ZEAL.DK

465.2

+1.48%↑

NOVO.B.DK

304

-1.31%↓

GMAB.DK

2,011

-0.49%↓

HLUNB.DK

42.86

+0.05%↑

ZEAL.DK

465.2

+1.48%↑

NOVO.B.DK

304

-1.31%↓

GMAB.DK

2,011

-0.49%↓

HLUNB.DK

42.86

+0.05%↑

ZEAL.DK

465.2

+1.48%↑

Search

Coloplast A-S (Class B)

Suletud

543.8 -0.87

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

540.6

Max

547.6

Põhinäitajad

By Trading Economics

Sissetulek

-107M

805M

Müük

28M

7B

P/E

Sektori keskmine

34.873

76.798

Aktsiakasum

3.88

Dividenditootlus

4.1

Kasumimarginaal

11.569

Töötajad

16,744

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+11.86% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

4.10%

2.37%

Turustatistika

By TradingEconomics

Turukapital

-9.9B

127B

Eelmine avamishind

544.67

Eelmine sulgemishind

543.8

Coloplast A-S (Class B) Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. dets 2025, 23:54 UTC

Kuumad aktsiad

Stocks to Watch: Nike, Cassava Sciences, KB Home

18. dets 2025, 23:51 UTC

Tulu

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

18. dets 2025, 23:39 UTC

Suurimad hinnamuutused turgudel

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

18. dets 2025, 22:57 UTC

Omandamised, ülevõtmised, äriostud

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

18. dets 2025, 21:40 UTC

Tulu

Nike Sales Tick Up, But China Weakness Persists

18. dets 2025, 23:56 UTC

Suurimad hinnamuutused turgudel

WiseTech Rises After Board Clears Executive Chair of Allegations

18. dets 2025, 23:45 UTC

Market Talk

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

18. dets 2025, 23:37 UTC

Market Talk
Tulu

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

18. dets 2025, 23:36 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

18. dets 2025, 23:03 UTC

Omandamised, ülevõtmised, äriostud

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

18. dets 2025, 23:02 UTC

Omandamised, ülevõtmised, äriostud

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

18. dets 2025, 23:00 UTC

Omandamised, ülevõtmised, äriostud

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

18. dets 2025, 22:59 UTC

Omandamised, ülevõtmised, äriostud

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

18. dets 2025, 22:58 UTC

Omandamised, ülevõtmised, äriostud

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

18. dets 2025, 22:57 UTC

Omandamised, ülevõtmised, äriostud

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

18. dets 2025, 22:56 UTC

Omandamised, ülevõtmised, äriostud

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

18. dets 2025, 22:55 UTC

Tulu

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18. dets 2025, 21:59 UTC

Tulu

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18. dets 2025, 21:50 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

18. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18. dets 2025, 21:35 UTC

Tulu

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

18. dets 2025, 21:31 UTC

Tulu

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q Greater China Rev Down 17% >NKE

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q EPS 53c >NKE

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q Apparel Rev $3.91B >NKE

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q Equipment Rev $550M >NKE

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q N Amer Rev $5.63B >NKE

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q Footwear Rev $7.66B >NKE

18. dets 2025, 21:15 UTC

Tulu

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

Võrdlus sarnastega

Hinnamuutus

Coloplast A-S (Class B) Prognoos

Hinnasiht

By TipRanks

11.86% tõus

12 kuu keskmine prognoos

Keskmine 901.38 DKK  11.86%

Kõrge 1,056 DKK

Madal 720 DKK

Põhineb 8 Wall Streeti analüütiku instrumendi Coloplast A-S (Class B) 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

8 ratings

2

Osta

4

Hoia

2

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat